Pembrolizumab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I.
In recent decades, rapid progression of monoclonal antibody (mAb) development has culminated in approvals for more than one hundred therapeutics in the United States. mAbs enhance the immune response ...
Research and development of monoclonal antibody (mAb) therapeutics is a vast and expanding area of drug discovery, largely due to mAb potential for high specificity and affinity towards target ...
Deletion and mutation of IL10RA gene on chromosome 11q23 to avert CpG-B oligodeoxynucleotides-induced apoptosis of human chronic lymphocytic leukemia B cells. Phase I study of the safety, ...
ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...
In therapeutic antibody development the fragment crystallizable (Fc) region is far more than just an antigen-binding aid; it's role is much larger, functioning as the antibody’s functional control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback